Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
US9587022B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2013 |
| Grant date | Mar 7, 2017 |
| Priority date | — |
| Expiry date | Dec 18, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.